{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hutchinson-Gilford+Syndrome",
    "query": {
      "condition": "Hutchinson-Gilford Syndrome"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T23:47:16.226Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06775041",
      "title": "Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hutchinson-Gilford Progeria Syndrome"
      ],
      "interventions": [
        {
          "name": "Progerinin",
          "type": "DRUG"
        },
        {
          "name": "Lonafarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PRG Science & Technology Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 10,
      "start_date": "2025-01-13",
      "completion_date": "2026-03",
      "has_results": false,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-07-23T23:47:16.226Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06775041"
    },
    {
      "nct_id": "NCT02579044",
      "title": "Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Progeria"
      ],
      "interventions": [
        {
          "name": "Everolimus and lonafarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "18 Months to 25 Years"
      },
      "enrollment_count": 80,
      "start_date": "2015-12",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-07-23T23:47:16.226Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02579044"
    },
    {
      "nct_id": "NCT04512963",
      "title": "Phase I Study of Progerinin in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hutchinson-Gilford Progeria Syndrome",
        "Werner Syndrome"
      ],
      "interventions": [
        {
          "name": "Progerinin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PRG Science & Technology Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 64,
      "start_date": "2020-08-24",
      "completion_date": "2021-07-27",
      "has_results": false,
      "last_update_posted_date": "2021-09-22",
      "last_synced_at": "2026-07-23T23:47:16.226Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04512963"
    },
    {
      "nct_id": "NCT00879034",
      "title": "A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Progeria",
        "Hutchinson-Gilford Syndrome"
      ],
      "interventions": [
        {
          "name": "Lonafarnib",
          "type": "DRUG"
        },
        {
          "name": "Zoledronic Acid",
          "type": "DRUG"
        },
        {
          "name": "Pravastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 5,
      "start_date": "2009-03",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2019-06-13",
      "last_synced_at": "2026-07-23T23:47:16.226Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00879034"
    },
    {
      "nct_id": "NCT00094393",
      "title": "Clinical Studies of Progeria",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Progeria"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "6 Months to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2004-10-14",
      "completion_date": "2018-05-22",
      "has_results": false,
      "last_update_posted_date": "2019-11-15",
      "last_synced_at": "2026-07-23T23:47:16.226Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00094393"
    },
    {
      "nct_id": "NCT00425607",
      "title": "Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Progeria",
        "Hutchinson-Gilford Syndrome"
      ],
      "interventions": [
        {
          "name": "Lonafarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Monica E. Kleinman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 29,
      "start_date": "2007-05",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2019-06-25",
      "last_synced_at": "2026-07-23T23:47:16.226Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00425607"
    },
    {
      "nct_id": "NCT00916747",
      "title": "Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Progeria"
      ],
      "interventions": [
        {
          "name": "Lonafarnib, Zoledronic Acid, and Pravastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 85,
      "start_date": "2009-08",
      "completion_date": "2023-12",
      "has_results": false,
      "last_update_posted_date": "2023-02-27",
      "last_synced_at": "2026-07-23T23:47:16.226Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00916747"
    }
  ]
}